



ASX release

8 October 2008

**US \$0.9m new pharmaceutical trial contract
US \$3.7m new contracts in past 130 days**

AtCor Medical (ASX:ACG), the developer and marketer of the SphygmoCor[®] system which measures central blood pressures and arterial stiffness non-invasively, today announced that it has signed a new agreement to supply SphygmoCor[®] systems and clinical trial support services to a leading international pharmaceutical company. The minimum total value of this contract is US\$930,000, the majority of which will be recognised in the current financial year. This new order brings the minimum total value of pharmaceutical trial contracts secured by AtCor in the past 130 days to over US \$3.7 million.

Duncan Ross, CEO of AtCor Medical, said: "We continue to execute on our strategy in pursuing the pharmaceutical clinical trials market. This new contract is not only evidence of the increasing importance of SphygmoCor[®] as a tool for understanding drug efficacy and mechanisms of action in pharmaceutical clinical trials but also reinforces its emerging importance as a drug therapy management tool in clinical practice. We look forward to continuing to build mutually beneficial relationships with our growing list of pharmaceutical trial customers."

Mr. Ross added, "The growing use of SphygmoCor[®] systems in clinical trials and the increasing volume of publications concerning central blood pressures and arterial stiffness indicate a move toward establishment of a new standard for cardiovascular risk assessment and management. Our rapid revenue growth is also a clear indication of the defensive nature of the healthcare industry in a challenging macro economic environment."

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company's SphygmoCor[®] system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 1,700 SphygmoCor[®] systems are currently in use worldwide at major medical institutions research institutions and in various clinical trials with leading pharmaceutical companies, and the company's technology have been featured in over 400 peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com

For further information, please contact:

Duncan Ross – AtCor Medical CEO
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO
+61 (2) 9874 8761

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au

SphygmoCor[®] is a registered trademark of AtCor Medical Pty Ltd and its related entities.